DB
RLMD icon

Dmitry Balyasny’s Relmada Therapeutics RLMD Stock Holding History

Dmitry Balyasny’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5M Buy
1,520,688
+1,268,231
+502% +$8.86M 0.01% 1035
2026
Q1 		$1.76M Sell
252,457
-295,397
-54% -$1.4M ﹤0.01% 1842
2025
Q4 		$2.65M Buy
+547,854
New +$1.84M ﹤0.01% 1728
2024
Q2 		– Sell
-12,322
Closed -$57.3K – 3020
2024
Q1 		$57.3K Buy
+12,322
New +$59.4K ﹤0.01% 2522
2022
Q4 		– Sell
-307,314
Closed -$11.4M – 3165
2022
Q3 		$11.4M Buy
307,314
+68,793
+29% +$1.91M 0.03% 628
2022
Q2 		$4.53M Buy
+238,521
New +$5.2M 0.01% 989

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dmitry Balyasny's RLMD Position: Q2 2026 in Review

Dmitry Balyasny increased its Relmada Therapeutics (RLMD) stake by 502% in Q2 2026, buying an estimated $8.86M and bringing the position to 1,520,688 shares worth $10.5M. The position accounts for 0.01% of the portfolio, ranked #1035.

Dmitry Balyasny first reported a position in RLMD in Q2 2022 and has held it in 6 quarters since. The position peaked at $11.4M in Q3 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Dmitry Balyasny held 1,520,688 shares of Relmada Therapeutics worth $10.5M as of Q2 2026.
  • Dmitry Balyasny bought 1,268,231 Relmada Therapeutics shares in Q2 2026, an estimated $8.86M.
  • Relmada Therapeutics made up 0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1035 holding.
  • Dmitry Balyasny first reported a position in Relmada Therapeutics in Q2 2022 and has held it in 6 quarters since.
  • Dmitry Balyasny's Relmada Therapeutics position peaked at $11.4M in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.